Study finds hope for oral hepatitis C regimen

01/19/2012 | Bloomberg

A study published in the New England Journal of Medicine found that 36% of hepatitis C patients who took the oral drug candidates daclatasvir and asunaprevir had undetectable viral loads after 24 weeks. Meanwhile, nine in 10 patients responded to the combination plus ribavirin and interferon. This is the first study to indicate that difficult-to-treat cases might respond without the aid of injectable interferon, said the lead researcher.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN